Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

NCT05786924 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT05786924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05786924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 18, 2023
Completion date
June 30, 2028
Enrollment
554 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

acquired resistance to kras g12c inhibitor, braf, braf gene mutation, braf mutation-related tumors, braf v600 mutation, braf v600e, brain metastases, colorectal cancer, colorectal carcinoma, histiocytic neoplasm, histiocytosis, kras g12a, kras g12d, kras g12f, kras g12r, kras g12v, kras g13c, kras g13d, kras mutation-related tumors, metastatic lung cancer, metastatic lung non-small cell carcinoma, non-small cell lung cancer, nras gene mutation, nsclc, recurrent histiocytic and dendritic cell neoplasm, recurrent lung cancer, recurrent lung non-small cell carcinoma, recurrent nsclc, solid carcinoma, solid tumor, thyroid cancer, thyroid carcinoma